Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra-abdominal infections.

@article{Bubrick1990CeftazidimeclindamycinVT,
  title={Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra-abdominal infections.},
  author={Melvin P. Bubrick and K L Heim-Duthoy and Albert E. Yellin and Thomas V. Berne and Peter N. R. Heseltine and Maria D. Appleman and David M. Cocchetto and Gary R. Matzke},
  journal={The American surgeon},
  year={1990},
  volume={56 10},
  pages={613-7}
}
In order to assess the efficacy and toxicity of ceftazidime as a substitute for aminoglycosides in the treatment of intra-abdominal sepsis, a prospective randomized trial was conducted. Ninety-four patients (49% trauma) were randomized to receive ceftazidime/clindamycin (CAZ/C) (n = 47) or tobramycin/clindamycin (T/C) (n = 47). CAZ (2.0 gm) and C (0.9 gm) were administered intravenously every 8 hours while T dosage was adjusted to maintain peak (5-8 mg/L) and trough (less than 2 mg/L… CONTINUE READING